HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, March 15 (HealthDay News) -- Pediatric cardiac centers and their referring hospitals are inconsistent about their sources for liquid captopril formulations used in children with heart failure, which could affect dosing and toxicity, according to a U.K. study published online March 15 in the Archives of Disease in Childhood.
Hitesh C. Pandya, and colleagues from Glenfield Hospital in Leicester, United Kingdom, performed a telephone survey of pharmacists and technical specialists from 13 pediatric cardiac centers and 13 large hospitals regarding their unlicensed liquid captopril formulations.
The researchers found that only four hospitals dispensed captopril tablets to crush and dissolve in water. The remaining 22 used nine different liquid formulations that came from a variety of sources including a National Health Service manufacturing unit, imports from Australia or in-house preparations. Only three cardiac centers and their referring hospitals used the same liquid captopril formulation, according to the study.
"This survey shows that pediatric cardiac centers and their referring hospitals use a variety of unlicensed liquid captopril formulations interchangeably," Pandya and colleagues conclude. "This degree of inconsistency raises issues about optimal captopril dosing and potential toxicity, such that its use may influence pediatric cardiac surgical and interventional outcomes."
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.